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ORIGINAL ARTICLE
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METHODS: The trinitrobenzene sulfonate (TNBS)
model of induced colitis was used in Balb/c mice. Subsequently after intravenous adeno-associated virusmediated regulatory T-cell epitopes (Tregitope) delivery,
acute colitis was initiated by intra-rectal administration
of 1.5 mg TNBS in 40% ethanol followed by a second
treatment with TNBS (0.75 mg in 20% ethanol) 8 d later. Control groups included mice not treated with TNBS
(healthy control group) and mice treated by TNBS only
(diseased group). At the time of sacrifice colon weight,
the disease activity index and histology damage score
were determined. Immunohistochemical staining of the
colonic tissues was performed to asses the cellular infiltrate and the presence of transcription factor forkhead
Box-P3 (Foxp3). Thymus, mesenteric lymph nodes, liver
and spleen tissue were collected and the corresponding
lymphocyte populations were further assessed by flow
cytometry analysis for the expression of CD4+ T cell
and regulatory T cell associated markers.
RESULTS: The Tregitope 167 treated mice gained an
average of 4% over their initial body weight at the
time of sacrifice. In contrast, the mice treated with
TNBS alone (no Tregitope) developed colitis, and lost
4% of their initial body weight at the time of sacrifice (P
< 0.01). The body weight increase that had been observed in the mice pre-treated with Tregitope 167 was
substantiated by a lower disease activity index and a
decreased colon weight as compared to the diseased
control group (P < 0.01 and P < 0.001, respectively).
Immunohistochemical staining of the colonic tissues
for CD4+ showed that inflammatory cell infiltrates
were present in TNBS treated mice with or without
administration with tregitope 167 and that these cellular infiltrates consisted mainly of CD4+ cells. For
both TNBS treated groups CD4+ T cell infiltrates were
observed in the sub-epithelial layer and the lamina
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AIM: To explore the anti-inflammatory potential of
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fected by IBD world-wide[10,11].
Recently, biological therapies that target immune pathways have emerged as a new therapeutic approach for the
treatment of immune-mediated diseases. They include
administration of monoclonal antibodies against inflammatory cytokines[12] and those that influence immune
responses such as certain small molecules, Helminths
and stem cells[10,13,14]. Since IBD are immune-mediated
diseases, these biological therapies are highly promising
treatment approaches and have the potential to achieve
mucosal tolerance and long-term remission in IBD[10,12-14].
Here, we introduce regulatory T-cell epitopes (Tregitopes)[15,16] as novel biological agents that could create
new possibilities for the regulation of inflammation and
postulate that Tregitopes, delivered by adeno-associated
virus (AAV), could be developed as a new therapeutic
modality for the treatment of IBD.
Tregitopes are a set of putative regulatory T cell
epitopes present in the immunoglobulin G molecule,
which have been identified by using computational epitope mapping[15,16]. Tregitope sequence 167 (Tregitope
167) and an additional sequence (Tregitope 289) were
synthesized and shown to bind to multiple Major Histocompatibility complex (MHC) class Ⅱ molecules and to
suppress immune response when co-administered with
an antigen. Tregitopes 167 and 289 were also shown to
expand natural occurring regulatory T (nTreg) cells and
to induce a regulatory phenotype and function in peripheral T (iTreg) cells[15,16]. Harnessing the potential of
Treg cells activated or induced by Tregitopes to regulate
pathological immune responses in IBD may reduce the
requirement for systemic immunosuppressive therapies.
However, the use of immunomodulatory peptides in
clinical applications for IBD so far have shown that the
in vivo delivery of these peptides for therapeutic purposes is hindered by difficulties in obtaining sufficient
and stable peptide concentrations[17-19]. Therefore, novel
means for stable delivery of regulatory peptides have to
be explored. AAV present a good safety profile and have
been shown to be effective as gene delivery vectors in
the clinic for the treatment of a broad range of diseases[20-22]. Therefore, AAV-mediated delivery represents an
attractive approach to deliver the immuno-modulatory
Tregitope peptides.
In the present study, the potential of AAV-mediated
gene therapy for the therapeutic delivery of Tregitope
167 was explored. Systemic AAV-mediated administration
of Tregitope 167 was shown to ameliorate the clinical and
histo-pathological severity of trinitrobenzene sulfonate
(TNBS) induced inflammatory colitis in mice. Hence,
AAV-mediated delivery of regulatory T-cell epitopes appears to be a promising novel therapeutic approach for
the treatment of IBD and could represent an alternative
or adjunct to the use of immunosuppressive drugs.

propria. CD4+ T cell infiltrates were also present in
the muscularis mucosa layer of the diseased control
mice, but were absent in the Tregitope 167 treated
group. Numerous Foxp3 positive cells were detected
in the lamina propria and sub-epithelium of the colon
sections from mice treated with Tregitope 167. Furthermore, the Foxp3 and glycoprotein A repetitions
predominant markers were significantly increased in
the CD4+ T lymphocyte population in the thymus of
the mice pre-treated with adeno-associated virus serotype 5 (cytomegalovirus promoter-Tregitope 167),
as cytomegalovirus promoter compared to lymphocyte
populations in the thymus of diseased and the healthy
control mice (P < 0.05 and P < 0.001, respectively).
CONCLUSION: This study identifies adeno-associated
virus-mediated delivery of regulatory T-cell epitope 167
as a novel anti-inflammatory approach with the capacity to decrease intestinal inflammation and induce longterm remission in inflammatory bowel disease.
© 2012 Baishideng. All rights reserved.
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INTRODUCTION
Inflammatory bowel diseases (IBD) are inflammatory
diseases that affect mostly young adults[1,2]. Although the
precise pathogenesis has not been identified, it is generally accepted that IBD result from inappropriate mucosal
immune system responses against intestinal flora and
other luminal antigens[3-5]. IBD are associated with a reduction in quality of life[6-8] and no curative treatments
are available.
Despite the fact that novel treatment strategies, including tumor necrosis factor (TNF)-neutralizing antibodies, have greatly expanded the therapeutic armamentarium, these therapeutics do not prevent complications
in IBD and many patients still have to undergo surgery[9].
New treatment strategies that would prevent the initiation
of inflammation and enable long-term remission would
improve the lives of millions of individuals who are af-
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MATERIALS AND METHODS
AAV vector production and characterization
Mouse Tregitope cDNA was synthesized (Integrated

4289

August 28, 2012|Volume 18|Issue 32|

van der Marel S et al . Tregitope 167 ameliorates experimental colitis
Day 0

Day 10

Day 18

Day 20

AAV5 injection, to ensure
that on the day of the colitis
induction the Tregitope are
being expressed

Intra-anal 1.5 mg TNBS
in 40% ethanol, for the
induction of acute colitis
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Figure 1 Schematic overview of the trinitrobenzene sulfonate induced colitis model. Mice were injected intravenously with either phosphate-buffered saline (PBS)
or adeno associated virus (AAV) 5 [cytomegalovirus (CMV) promoter T-cell epitopes (Tregitope) 167]. Ten days after AAV-mediated Tregitope delivery acute colitis was
initiated by intra-rectal administration of 1.5 mg trinitrobenzene sulfonate (TNBS) in 40% ethanol followed by a second TNBS treatment (0.75 mg in 20% ethanol) 8 d
later. Control groups consisted of mice not treated by TNBS (healthy control group) and mice treated by TNBS only (diseased control group).

transfer mice models using AAV vectors[27,29].

DNA Technologies, IDT, Inc) according to the published
corresponding sequence[15,16] and cloned into the plasmid
pPSC10[23] under the control of the cytomegalovirus
(CMV) promoter. The Woodchuck hepatitis virus posttranscriptional enhancer was incorporated behind the
Tregitope 167 cDNA to further optimize gene expression[24]. The AAV vector, AAV5 (CMV-Tregitope 167)
was produced according to a technology adapted from
Negrete et al[23]. The AAV vector was purified with an
anion column using the ÄKTA explorer system (GEHealthcare). After purification, the concentration of
AAV vector genomes copies (genome copies/mL) was
determined at 9 × 1013 genome copies/mL by Taqman
qPCR amplification. The biological infectivity of AAV5
(CMV-Tregitope 167) was demonstrated in vitro by PCR
amplification of the “CMV-Tregitope 167” DNA fragment (product size 402 bp) on DNA isolated from
HEK293T transduced with AAV5 (CMV-Tregitope 167).
Primers designed and synthesized for Tregitope 167 and
the CMV promoter were used.

Assessment of inflammation
The body weights of the mice were recorded daily, and
wasting disease progression was expressed by the percentage of weight loss as compared to body weight at
the day of initiation of TNBS treatment (day 10, Figure
1). Animals were withdrawn from the study when their
weight loss was > 25% of their original body weight. At
the time of sacrifice, colons were collected and presence
of loose stool and visible fecal blood was assessed.
At the time of sacrifice, a composite score [disease
activity index (DAI)] was established as described previously[25]. Body weight loss was scored on a scale of 0-4 (0,
< 1%; 1, 1%-5%; 2, 5%-10%; 3, 10%-15%; 4, > 15%).
Loose stool was scored on a scale of 0-4 (0, normal; 1,
loose droppings; 2, loose stools, colon filled with feces;
3, loose stool, feces only near cecum; 4, empty bowel).
Visible fecal blood was scored on a scale of 0-4 (0, negative; 2, positive; 4, gross bleeding). The DAI consists of a
combination of body weight loss, loose stool and visible
fecal blood scores divided by 3 as described previously[25].
Colon tissue weights were recorded and used as an
indicator of disease-related intestinal wall thickening.
Increased colon weight has been shown to correlate with
increased colon inflammation[25]. Colons were first divided longitudinally into two parts: one part was immediately frozen in liquid nitrogen for protein extraction and
cytokine determination, while the second part was stored
in formalin and embedded in paraffin for (immuno-)
histological evaluation. Blood was collected by orbital
puncture immediately following sacrifice and plasma
was separated by centrifugation (5000 r/min for 5 min).
Plasma samples were stored at -80 ℃ until analysis.

Induction of colitis and study design
Balb/c mice (males, age 6-8 wk) were obtained from
Harlan Laboratories, the Netherlands. The experimental protocol was approved by the ethical committee for
animal welfare of the AMC (Academic Medical Center,
Amsterdam, the Netherlands). Colitis was induced in
mice by administration of TNBS (TNBS, Sigma-Aldrich),
as described previously[25]. The general procedure is summarized in Figure 1.
Mice were injected intravenously with either phosphate-buffered saline or AAV5 (CMV-Tregitope) 10 d
before acute colitis was initiated by intra-rectal administration of 1.5 mg TNBS in 40% ethanol. Consecutively,
a second TNBS treatment (0.75 mg in 20% ethanol) was
done 8 d after the first TNBS treatment as described
precedently[25]. Mice not treated with TNBS (healthy control group) and mice treated with TNBS only (diseased
control group) were used as references to monitor colitis
development. A concomitant sham AAV control vector
was not used in this study as this control has been shown
to be equivalent to saline control[26,27]. Even though AAVmediated gene transfer leads to the development of neutralizing antibodies against the vector capsid[28], preventing vector re-administration, no inflammatory responses
against the AAV capsid were documented in in vivo gene

WJG|www.wjgnet.com

Histological analysis
Colonic segments were fixed in 10% formalin overnight
and thereafter stored in 70% ethanol before embedding
in paraffin. Tissues sections (7 μm thick) were stained
with haematoxylin and eosin (HE) for histology scoring.
The histology damage score was calculated using the following criteria: percentage of area involved, number of
follicle aggregates, edema, fibrosis, erosion/ulceration,
crypt loss, and infiltration of mononuclear and polymorphonuclear cells, as described previously[30]. The percentage of area involved and crypt loss were scored on a scale
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of 0-4 (0, normal; 1, < 10%; 2, 10%; 3, 10%-50%; and 4,
> 50%). Erosions were defined as 0 if the epithelium was
intact, 1 if the lamina propria was involved, 2 if ulcerations involved the submucosa, and 3 when ulcerations
were transmural. The severity of the other parameters
was scored on a scale of 0-3 (0, absent; 1, weak; 2, moderate; and 3, severe)[30]. A certified pathologist scored all
the tissue sections (blinded analysis).

105

% of day 0 body weight

100

Immunohistochemistry
Colon tissues sections of 7 μm were aceton-fixed and sta
ined with rat-anti-mouse (ram) CD4 (1:100, BD550278),
ram CD8a (1:50, BD550281), ram CD19 (1:50,
BD550284), ram Foxp3 (1:100, eBiosciences14-5773-82)
and ram F4/80 (1:500). Prior to anti-rat biotin conjugated
secondary antibody (1:50, BD51-7605kc) and Streptavidin-HRP (BD) incubations, endogenous peroxidases were
blocked by incubation with 0.3% H2O2 for 20 min. After
5 min of diaminobenzidine staining (BD), the sections
were counter-stained with Haematoxylin, dehydrated and
mounted in Entallan.
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Figure 2 Adeno associated virus serotype 5 mediated delivery of regulatory T-cell epitope 167 ameliorates trinitrobenzene sulfonate induced
colitis development over time. Mice were injected intravenously with either
phosphate-buffered saline (PBS) or adeno associated virus (AAV) 5 [cytomegalovirus (CMV) promoter T-cell epitopes (Tregitope) 167]. 10 d after AAV-mediated Tregitope delivery, acute colitis was initiated by intra-rectal administration of
1.5 mg trinitrobenzene sulfonate (TNBS) in 40% ethanol followed by a second
TNBS treatment (0.75 mg in 20% ethanol) 8 d later. Control groups consisted
of mice not treated by TNBS (healthy control group) and mice treated by TNBS
only (diseased control group). Disease progression was assessed by changes
in daily body weight. Animals were withdrawn from the study when their weight
loss was > 25% of their original body weight. Overall for the healthy controls,
n = 9; adeno associated virus (AAV) 5 (CMV-Tregitope 167) treated, n = 7;
diseased controls, n = 6, were included in the analysis. The data were analyzed
using a 1 way analysis of variance, followed by Dunn’s post hoc test for multiple
comparisons. Data are presented as mean ± SE of all the mice. bP value < 0.01
between PBS (diseased control group) and both AAV5 (CMV-Tregitope 167)
treated and the healthy control group.

Flow cytometry
Thymus, mesenteric lymphoid nodes, liver and spleen
tissue were collected upon sacrifice. Cell suspensions
obtained from each of the tissue samples were prepared
using 40 μm cell strainers (BD Biosciences) and stained
for T cell surface markers CD4 (clone RM4-5, eBioscience), CD8 (Clone 53-6.7, Miltenyi) and Treg cell surface
markers glycoprotein A repetitions predominant (GARP)
and CD25 (clone YGIC86 and clone PC61.5 respectively,
both eBioscience) as well as for the intracellular Treg cell
marker Foxp3 (clone FJK16, eBioscience). The analysis
was performed by flow cytometry (FACSCalibur, BD
Biosciences).

severity and is indicative of differences in colitis development between experimental groups[31]. Animals were withdrawn from the study when their weight loss was > 25%
of their original body weight.
The body weight of the mice was monitored daily
after the first TNBS treatment as an indication of the
severity in the colitis development between experimental groups (Figure 2). TNBS treated mice that were preadministered with Tregitope 167, showed a body weight
that increased over time and was comparable to the weigh
gain of untreated healthy control mice (Figure 2). The
Tregitope 167 treated mice gained an average of 4% over
their initial body weight at the time of sacrifice (Figure
3A). In contrast, the mice treated with TNBS alone (no
Tregitope) developed colitis, and lost 4% of their initial
body weight at the time of sacrifice (Figure 3A).
Increases in colon weight, as well as in the disease
activity index are both indicative of colonic inflammation
and were determined at the time of sacrifice (Figure 3).
The body weight increase that had been observed in the
mice pre-treated with Tregitope 167 was substantiated by
a lower disease activity index (Figure 3B) and a decreased
colon weight (Figure 3C) as compared to the diseased
control group (P < 0.01 and P < 0.001 respectively).
The histology damage score was performed on HE

Statistical analysis
The results are presented as mean ± SD or SE, where
appropriate. Statistical analyses were performed using
Prism 5.0 (GraphPad). Data were analyzed using a 1 way
analysis of variance, followed by Dunn’s post hoc test for
multiple comparisons.

RESULTS
We investigated the potential for AAV5-mediated delivery
of regulatory T-cell epitopes to prevent the development
of TNBS induced colitis. Mice treated intra-rectally with
TNBS in ethanol developed a severe illness as reflected in
the progressive body weight loss over time and an increase
in disease activity index, histology damage score and mucosal inflammatory parameters at the time of sacrifice.
Tregitope 167 delivery protects against TNBS colitis
development
Development of colitis in the TNBS mice model is str
ongly associated with wasting disease[31]. Daily weight
determination is therefore important to determine colitis

WJG|www.wjgnet.com
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Figure 3 Adeno associated virus serotype 5 mediated delivery of regulatory T-cell epitope 167 alleviates colonic inflammation as determined at the day of
sacrifice. Mice were injected intravenously with either phosphate-buffered saline (PBS) or adeno associated virus (AAV) 5 [cytomegalovirus (CMV) promoter T-cell
epitopes (Tregitope) 167]. Ten days after AAV-mediated Tregitope delivery acute colitis was initiated by intra-rectal administration of 1.5 mg trinitrobenzene sulfonate
(TNBS) in 40% ethanol followed by a second treatment with TNBS (0.75 mg in 20% ethanol) 8 d later. Control groups consisted of mice not treated by TNBS (healthy
control group) and mice treated by TNBS only (diseased control group). Disease progression was assessed by changes in daily body weight as well as macroscopic
and microscopic scores on the day of sacrifice. A: Animal body weight change on day 20 upon sacrifice. The values of body weight are expressed as a percentage of
body weight on the day of the first TNBS treatment; B: Macroscopic disease score. The disease activity index consist of a combination of body weight loss, loose stool
and visible fecal blood scores divided by 3 at the day of sacrifice; C: Assessment of colonic weight upon sacrifice as an index of disease-related intestinal wall thickening; D: Histological grading of colonic colitis scores. The histology damage score was calculated using the following criteria: percentage of area involved, number of
follicle aggregates, edema, fibrosis, erosion/ulceration, crypt loss, and infiltration of mononuclear and polymorphonuclear cells. Individual mice are depicted; from the
AAV5 (CMV-Tregitope 167) pre-treated group an outliner was removed. Animals were withdrawn from the study when their weight loss was > 25% of their original
body weight. Overall for the healthy controls, n = 9; AAV5 (CMV-Tregitope 167) treated, n = 6; diseased controls, n = 6, were included in the analysis. The data were
analyzed using a 1 way analysis of variance, followed by Dunn’s post hoc test for multiple comparisons. Data are presented as mean ± SD of all the mice. aP < 0.05,
b
P < 0.01 vs PBS (diseased control group).

stained tissue sections. The score was calculated using the
following criteria: percentage of area involved, number
of follicle aggregates, edema, fibrosis, erosion/ulceration,
crypt loss, and infiltration of mononuclear and polymorphonuclear cells. The histological scoring showed that the
AAV5 (CMV-Tregitope 167) pre-treated mice presented a
decreased severity of colitis as compared to the diseased
control group (Figure 3D) as a result of lower levels of
inflammation, namely decreased cellular infiltrations, little
crypt loss and the absence of erosions and ulceration
(Figure 4).
The TNBS induced colitis model is characterized by

WJG|www.wjgnet.com

the local infiltration of CD4+ T cells in the intestinal
mucosa[32]. Immunohistochemical staining of the colonic
tissues for CD4+ showed that, at the day of sacrifice, inflammatory cell infiltrates were present in TNBS treated
mice with or without administration with Tregitope 167
and that these cellular infiltrates consisted mainly of
CD4+ cells. For both TNBS treated groups CD4+ T
cell infiltrates were observed in the sub-epithelial layer
and the lamina propria. CD4+ T cell infiltrates were also
present in the muscularis mucosa layer of the diseased
control mice, but were absent in the AAV5 (CMV-Tregitope 167) pre-treated group (Figure 5).
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Figure 4 Hematoxylin and eosin-stained paraffin section from colon tissue. A, B: Healthy control mice; C, D: Diseased control mice; E, F: Adeno associated
virus (AAV) 5 [cytomegalovirus (CMV) promoter T-cell epitopes (Tregitope) 167] pre-treated mice. Histological evidence that AAV5 (CMV-Tregitope 167) ameliorates
trinitrobenzene sulfonate (TNBS)-induced pathology. Images depicted of an HE-stained paraffin section of a representative mouse colon from each group at the moment of sacrifice. The images of the diseased control (C, D) demonstrated acute inflammation: elongated villi, abundant transmural cellular infiltrate, erosions and
crypt loss as compared to both the AAV5 (CMV-Tregitope 167) pre-treated and healthy control mice.

Increase of regulatory markers expression in the
intestinal mucosa and thymus of mice administered with
Tregitope 167
The reported ability of Tregitopes to both activate and
induce Treg cells led us to further assess the presence of
Treg-cell associated markers in the colonic tissues.
Colon tissues were prepared and the presence of
transcription factor Foxp3 was assessed by immunohistochemistry, so as to determine whether regulatory T cells
were present in the peri-colonic infiltrates[33]. Numerous
Foxp3 positive cells were detected in the lamina propria
and sub-epithelium of the colon sections from mice
treated with Tregitope 167 (Figure 6). Foxp3 positive cells
were absent or sporadic in the colon of healthy and diseased control mice (Figure 6).

WJG|www.wjgnet.com

Thymus, mesenteric lymph nodes, liver and spleen tissue were collected at the time of sacrifice and the corresponding lymphocyte populations were further assessed
by flow cytometry analysis for the expression of the CD4
T cell surface marker and the Treg cell associated markers Foxp3[34], CD25[35] and GARP[36,37] (Figure 7A-F). The
Foxp3 and GARP markers were significantly increased
in the CD4+ T lymphocyte population in the thymus of
the mice pre-treated with AAV5 (CMV-Tregitope 167), as
compared to lymphocyte populations in the thymus of
diseased and the healthy control mice (P < 0.05 and P <
0.001 respectively, Figure 7G). CD4+ thymic lymphocyte
population (mean ± SD, 11% ± 2%, n = 6) co-expressed
Foxp3 and GARP in the thymus of AAV5 (CMVTregitope 167) pre-treated mice as compared to the
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Figure 5 Immunohistochemistry pictures depicting CD4 staining colon tissue. A, B: Healthy control mice; C, D: Diseased control mice; E, F: Adeno associated
virus (AAV) 5 [cytomegalovirus (CMV) promoter T-cell epitopes (Tregitope) 167] pre-treated mice. Specific immunohistochemical staining showed inflammatory cell infiltrates present in trinitrobenzene sulfonate (TNBS) treated mice with or without administration with Tregitope 167 consisted of CD4 positive cells, localized in the subepithelial layer, in the lamina propria (C-F) and for the diseased control also in the muscular layer (C,D). Depicted are representative data from a single mouse.

thymic lymphocyte population of diseased (mean ± SD,
7% ± 3%, n = 6) and the healthy control groups (mean
± SD, 6% ± 2%, n = 9), respectively (Figure 7G). Both
the relative and absolute number of Foxp3 expressing
T cells were expanded in the thymus after AAV5 (CMVTregitope 167) pre-treatment (Figure 7H). No significant
differences in the expression of Foxp3 and GARP in the
lymphocyte populations of the mesenteric lymph nodes,
liver and spleen were identified.

peripheral tolerance, preventing autoimmune diseases
and limiting chronic inflammation[33,38]. Therefore, novel
strategies that aim for therapeutic tolerance induction and
leverage Treg cells are currently being explored[39]. In the
present study, the potential for AAV-mediated delivery
of an immunomodulatory peptide (Tregitope 167) was
investigated.
In this study, we demonstrate that the systemic AAVbased delivery of Tregitope 167 has the potential to prevent the development of fulminant colitis in a TNBSinduced model of IBD. Tregitope 167 was used in our
study as its binding affinity for the MHC molecule in
Balb/c mice is superior to Tregitope 289 (De Groot,
manuscript submitted for publication). The significant
decrease of colonic inflammation in the Tregitope 167

DISCUSSION
Curative treatment approaches for Crohn’s disease and ulcerative colitis represent a significant unmet medical need.
Regulatory T (Treg) cells are key players in maintaining
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Figure 6 Immunohistochemistry pictures depicting forkhead Box-P3 staining colon tissue. A, B: Healthy control mice; C, D: Diseased control mice; E, F: Adeno
associated virus (AAV) 5 [cytomegalovirus-regulatory (CMV) promoter T-cell epitopes (Tregitope) 167] pre-treated mice. Colon tissue were prepared and assessed by
immunohistochemistry for the expression of the transcription factor forkhead Box-P3 (Foxp3) as a marker for regulatory T cells. Numerous Foxp3 positive cells were
detected in the lamina propria and sub-epithelium of the colon sections from mice treated with Tregitope 167 (E, F). Foxp3 positive cells were rarely present in the
colon of healthy and diseased control mice (A-D). Depicted are representative data from a single mouse.

pre-treated mice was reflected in an overall weight gain
and substantiated by a decreased disease activity index,
colon weight and histology damage score at the time of
sacrifice. Additionally, there was less mucosal inflammation in the AAV (CMV-Tregitope 167) pre-treated mice.
This therapeutic benefit corresponded with increases in
the relative number of T cells expressing regulatory T cell
markers in the colon tissues and among thymic lymphocytes of the Tregitope 167-treated mice.
IBD patients do not present defects in regulatory T
cell function or phenotype[40-42] and by consequence are
more likely to benefit from therapies aiming at inducing
and expanding Treg cells than patients affected by other
autoimmune diseases. Tregitope 167 has the potential to
both activate nTreg cells and induce iTreg cells[15,16] and
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may be suitable as a novel therapeutic agent for IBD.
However, the use of immunomodulatory peptides in clinical applications for IBD has been hindered by difficulties
associated with the systemic delivery of the therapeutic
peptides in sufficient quantity and concentration to the
target tissues[17-19]. AAV has proven to be both effective
and safe as a gene therapy delivery vector in the clinic[20-22]. Therefore, AAV-mediated delivery of Tregitopes
was explored in this study. The AAV serotype 5 (AAV5)
was used since pre-existing immunity to AAV5 in humans
has been shown to be low[28,43]. Our data demonstrate that
AAV5-mediated delivery may be an efficient approach for
stable administration of Tregitopes in vivo. Further studies
will need to be performed to determine the duration of
the immunological tolerance that is evoked by induction
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Figure 7 Adeno associated virus serotype 5 mediated delivery of regulatory T-cell epitope 167 induces forkhead Box-P3 and glycoprotein A repetitions predominant expression in the CD4 positive thymic lymphocyte population. Thymus tissue was collected upon sacrifice. Cells suspensions were prepared and stained for the
following markers: CD4, glycoprotein A repetitions predominant (GARP) and forkhead Box-P3 (Foxp3) before analysis by flow cytometry (FACSCalibur, BD Biosciences). A:
Histogram Foxp3 cell count: healthy control; B: Histogram GARP cell count: healthy control; C: Histogram Foxp3 cell count: diseased control; D: Histogram GARP cell count:
diseased control; E: Histogram Foxp3 cell count: adeno associated virus (AAV) 5 [cytomegalovirus (CMV) promoter T-cell epitopes 167] pre-treated group (grey, filled in)
vs unstained control (black continuous line). Gating was done on the CD4 positive thymic lymphocyte population. Depicted are representative data from a single mouse; F:
Histogram GARP cell count: AAV5 (CMV-Tregitope 167) pre-treated group (grey, filled in) vs unstained control (black continuous line). Gating was done on the CD4 positive thymic lymphocyte population. Depicted are representative data from a single mouse; G: Depicted are percentages of CD4 positive, Foxp3 positive and GARP positive
thymic lymphocytes. Individual mice are depicted; for the a AAV5 (CMV-Tregitope 167) pre-treated group one mouse did not have a thymus and therefore n = 6 mice were
included in this analysis. The data were analyzed using a 1 way analysis of variance, followed by Dunn’s post hoc test for multiple comparisons. Data are presented as mean
± SD of all the mice. aP < 0.05, bP < 0.01 vs phosphate-buffered saline (PBS) (diseased control group) or healthy control; H: Both the relative and absolute number of Foxp3
expressing T cells were expanded in the thymus after AAV5 (CMV-Tregitope 167) pre-treatment. Mean % of lymphocytes expressing Foxp3 in the thymus of the three groups
are depicted; for the AAV5 (CMV-Tregitope 167) pre-treated group one mouse did not have a thymus and therefore n = 6 mice were included in this analysis.
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and activation of Treg cells.
Regulatory T (Treg) cells are considered to be essential
in the counter-regulation of inflammatory reactions and
Foxp3 is considered as a marker of the regulatory phenotype[34,44,45]. Staining for Foxp3 in mice pre-treated with
Tregitope 167 revealed the presence of Foxp3 positive
cells in the lamina propria and sub-epithelium of the colon sections. Additionally, expression of both Foxp3 and
GARP were increased in the thymic CD4+ T lymphocyte
population in mice pre-treated with AAV5 (CMV-Tregitope 167), indicating an increase in activated regulatory
T-cells[34,36,37,44,45]. The presence of higher numbers of activated regulatory T cells corresponded with the prevention
of fulminant intestinal inflammation in vivo in this TNBS
model of IBD.
No increase in the Treg cell populations was observed
in the mesenteric lymph nodes, liver and spleen in the
current study. We hypothesize that this could be due to
the duration of the experiment and the timing of the
Treg cell evaluation. In other mouse models such as the
model of spontaneous encephalomyelitis, the de novo generation of Treg cells was initiated intrathymically, and was
followed by Foxp3 induction in peripheral tissue at later
time points[46].
Tregitopes are T cell epitopes naturally located in immunoglobulins that bind to multiple MHC class Ⅱ alleles
and induce Treg cell responses. We have demonstrated
that antigen presenting cells (APCs) present Tregitopes
to nTreg cells, engage feedback mechanisms promoting
a tolerogenic APC phenotype, induce Treg cell expansion, and modulate antigen-specific effector T cell responses (Cousens and De Groot, manuscript submitted
for publication). Proportions of APC expressing MHC
Ⅱ, CD80, and CD86 are suppressed, consistent with reported effects of intravenous immunoglobulin[47] and of
the immunoglobulin (Ig) G-derived peptide hCDR1[48].
The basic mechanism of Tregitope tolerance induction
is currently proposed to be as follows: (1) APC present
Tregitopes to nTreg cells; (2) nTreg cells are activated to
proliferate; (3) nTreg cells provide tolerogenic feedback
signals to APC, modulating the APC phenotype; and
(4) nTreg cells and tolerogenic APC together suppress
antigen-specific T cell responses (Cousens and De Groot,
manuscript submitted for publication).
A limitation of the colitis model used in this study
was the acute necrotizing enterocolitis, occurring in the
first 3 d after the first TNBS treatment, a presentation
of disease which is unrelated to IBD[25]. Therefore the
surviving number of mice, included in the analysis was
lower than anticipated, which, for some analysis, conflicted with statistical analysis of the data. As a consequence,
a large variability in the colon mucosa cytokines levels
was observed after TNBS induced experimental colitis
and prevented an accurate analysis of those parameters.
Therefore, further development of AAV mediated delivery of Tregitope 167 in different experimental models
of inflammatory disease will be necessary to confirm the
obtained results.
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In summary, our data provide preliminary evidence
supporting the potential use of AAV-based Tregitope
delivery as a therapy for the treatment of IBD. Further
investigations will permit to define the mechanism by
which Tregitope exert their immune regulatory properties, the duration of the effect, the ability of Tregitopes
to reduce disease that has already been established and
their eventual impact on systemic immunity.
Overall, this study identifies AAV-mediated delivery
of regulatory T-cell epitope 167 as a novel anti-inflammatory approach with the capacity to decrease intestinal
inflammation and induce long-term remission in IBD.
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diseases (IBD) is tolerance induction. In other words, exploring different mechanisms by which the immune system could maintain unresponsiveness to the antigens in the mucosal environment which cause destructive immune responses
and thereby disease activity in IBD patients.

Research frontiers

The recently discovered regulatory T cell epitopes (Tregitopes) are highly
promising peptides that were demonstrated to both activate and induce regulatory T cells in vitro and in vivo. Modulation of T cell responses with Tregitopes
may contribute to the regulation of pathological inflammatory responses in IBD.
However, the use of immunomodulatory peptides in clinical applications for IBD
so far have shown that the in vivo delivery of these peptides for therapeutic
purposes is hindered by difficulties in obtaining sufficient and stable peptide
concentrations.

Innovations and breakthroughs

This study identifies adeno-associated virus (AAV)-mediated delivery of regulatory T-cell epitope as a novel anti-inflammatory approach with the capacity to
decrease intestinal inflammation and induce long-term remission in IBD.

Applications

The significance of the achievements to IBD relate to possible novel therapeutic
approaches, which could aim at long term tolerance induction. The described
study identifies a novel anti-inflammatory strategy with the capacity to ameliorate
the intestinal inflammatory response and restore mucosal immune tolerance.

Terminology

Tregitopes are T cell epitopes naturally located in immunoglobulins that bind to
multiple major histocompatibility complex class Ⅱ alleles and induce regulatory
T cell responses. The non-pathogenic, replication-deficient AAV holds promise for gene therapy. The AAV vector has a good safety profile as it remains
predominantly episomal. The therapeutic potential of AAV as a vector in gene
therapy has also been demonstrated in a clinical setting in recent studies.
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This interesting paper is investigating the possibility of AAV mediated delivery
of regulatory trinitrobenzene sulfonate (TNBS) colitis. The major finding of the
study was that systemic administration of AAV was associated with a marked
decrease in the clinical and histological severity of the TNBS induced inflammatory colitis parallel with an increase of the T lymphocytes expressing regulatory
markers in the colon and thymus. Overall, this manuscript presents an interesting approach opening new possibilities.
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